Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    e7208
Show Display Options
Rank Status Study
1 Recruiting Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy
Condition: Colorectal Cancer
Interventions: Biological: cetuximab;   Biological: ramucirumab;   Drug: irinotecan hydrochloride

Indicates status has not been verified in more than two years